(Cefoperazone sodium + sulbactam sodium) is a Small Molecule owned by Pfizer, and is involved in 2 clinical trials, which were completed.

Cefoperazone inhibits penicillin-binding proteins (PBPs). It binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. Sulbactam is a beta-lactamase inhibitor given in combination with beta-lactam antibiotics to inhibit beta-lactamase, an enzyme produced by bacteria that destroys the antibiotics.

The revenue for (Cefoperazone sodium + sulbactam sodium) is expected to reach a total of $24.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Cefoperazone sodium + sulbactam sodium) NPV Report.

(Cefoperazone sodium + sulbactam sodium) is currently owned by Pfizer.

(Cefoperazone sodium + sulbactam sodium) Overview

Cefoperazone Sodium and Sulbactam sodium (Sulperazone, Magnex, Magnex Forte) is a fixed combination of cephalosporin antibiotic and beta-lactamase inhibitor. It is formulated as injectable powder for solution for  intravenous route of administration. Sulperazone is indicated in the treatment of sepsis, infective endocarditis, trauma, burns, secondary infection pharynx, laryngitis, tonsillitis, acute bronchitis, pneumonia, lung abscess, empyema, chronic respiratory disease, bladder flame, pyelonephritis, peritonitis, intra-abdominal abscess, cholecystitis, cholangitis, liver abscess and bartholinitis.

Pfizer Overview

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.

Quick View – (Cefoperazone sodium + sulbactam sodium)

Report Segments
  • Innovator (Non-NME)
Drug Name
  • (Cefoperazone sodium + sulbactam sodium)
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Ear Nose Throat Disorders
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Infectious Disease
  • Ophthalmology
  • Respiratory
  • Women’s Health
Key Companies
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.